Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.

Gordon L. Phillips,Barry Meisenberg,D. E. Reece,V. R. Adams,A. Badros,J. Brunner,Robert G. Fenton,Joanne Filicko,D.L. Grosso,G. A. Hale,Dianna S. Howard,V. P. Johnson,A. Kniska,K. W. Marshall,Bijoyesh Mookerjee,R. Nath,Aaron P. Rapoport,Clarence Sarkodee-Adoo,Naoko Takebe,David H. Vesole,John L. Wagner,Neal Flomenberg

Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.

2004

Activity of single-agent melphalan 220–300 mg/m 2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

Keywords:

Lymphoma
Amifostine
Immunology
Hematology
Stem cell
Medicine
Cytoprotection
Melphalan
Internal medicine
Hematopoietic stem cell
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations